Biopharma Data Silos Aren’t Just a Technology Problem — Why AI Readiness Requires More Than Connecting Systems
- Muna Zain
- Aug 20
- 8 min read
Biopharma organizations have access to more data than ever before: Claims, EMR, Specialty pharmacy, Patient services, CRM, Market research, Digital engagement, Payer data, Clinical information, Financial forecasts, and Competitive intelligence. Yet one of the most common challenges facing commercial leaders remains surprisingly basic: How do we bring the right information together to make a better business decision?
As artificial intelligence becomes a larger part of the biopharma agenda, that question is becoming even more important. The temptation is to view fragmented data as primarily a technology problem—something that can be solved by moving everything into a data lake, implementing a new platform, or connecting another set of systems.
But, biopharma data fragmentation is more complicated. Data often operates under different regulatory, contractual, technical, and organizational requirements. Understanding those differences is essential before an organization can create a scalable analytics or AI capability. The objective therefore should not necessarily be to eliminate every data silo. It should be to create the right connections between the right data to support the right business decisions—with appropriate governance.
Why Biopharma Data Becomes Fragmented
Consider a simplified patient journey: Diagnosis → Treatment Decision → Access → Specialty Pharmacy → Patient Support → Adherence → Outcomes.
From a commercial strategy perspective, that may appear to be one continuous journey. From a data perspective, however, it may involve multiple completely different environments: EMR → Claims → Specialty Pharmacy → Hub → CRM → Market Research → Digital → Finance.
Each source may have a different owner, vendor, patient identifier, refresh frequency, data model, permitted use, quality standard, and governance process. This creates fragmentation long before AI enters the discussion.
The infographic below highlights the contrast between the continuous patient journey and the fragmented data ecosystem behind it.
Four Factors Are Particularly Important.
1. Regulatory and Privacy Requirements
Healthcare data is not governed like ordinary commercial information. HIPAA, for example, establishes protections for individually identifiable health information handled by covered entities and certain business associates. Its Privacy Rule includes the principle of limiting certain uses and disclosures of protected health information to the minimum necessary for the intended purpose. Importantly, HIPAA does not automatically apply to every pharmaceutical manufacturer in every circumstance, but biopharma companies frequently interact with healthcare organizations, health plans, patient-service providers, and other partners operating within HIPAA-regulated environments.
De-identification can make health information available for broader analytical purposes, but even this involves specific HIPAA standards and contractual considerations. HHS guidance recognizes two methods for de-identifying protected health information under the Privacy Rule.
Clinical and regulatory data can operate under a different set of controls. FDA requirements governing electronic records, including 21 CFR Part 11 where applicable, emphasize the trustworthiness and reliability of electronic records and may involve controls such as validation, access management, audit trails, and record retention.
For global biopharma organizations, the complexity grows further.
Under the European Union's GDPR, organizations must follow principles including purpose limitation and data minimization, while health information receives heightened protection as sensitive personal data. Moving personal information outside the EU may also require specific safeguards such as adequacy mechanisms, Standard Contractual Clauses, or other approved transfer mechanisms.
And privacy requirements increasingly extend beyond traditional HIPAA-regulated health information. Washington's My Health My Data Act, for example, specifically addresses certain consumer health data outside HIPAA's traditional scope and establishes requirements related to collection, sharing, consent, deletion, and sale.
The result is an important distinction:
Regulation does not necessarily mandate data silos—but it can make unrestricted data integration inappropriate, complex, or operationally expensive.
That distinction matters.
2. Contractual and Vendor Restrictions
Even when regulations permit a particular analytical use, contracts may impose additional boundaries. Biopharma organizations frequently rely on external partners for claims data, specialty pharmacy feeds, patient services, market research, CRM platforms, digital analytics, and other commercial information.
Those relationships may include specific provisions governing:
Permitted uses of the data
Who may access it
Whether patient-level records may be linked
Whether data may be transferred to another vendor
Whether information can be used for modeling or AI
How long data can be retained
Whether derived datasets can be created
HIPAA business associate arrangements themselves may also define and limit permissible uses and disclosures of protected health information. This means an organization can technically possess several valuable datasets without necessarily having unrestricted permission to combine or repurpose them. For AI initiatives, this becomes especially important. The question isn't simply: “Do we have the data?”
It is also: “Do we have the right to use the data for this purpose?”
3. Technical Fragmentation
Then there is the technology itself. Different datasets may use entirely different structures and identifiers:
One source may identify a healthcare provider by NPI.
Another may use a CRM customer ID.
Patient-level claims may use de-identified tokens.
A specialty pharmacy may operate with another identifier entirely.
Refresh frequencies can also vary dramatically.
Sales information might update daily or weekly.
Claims can carry significant lag.
Market research may arrive quarterly.
Forecasts may be updated monthly.
CRM activity may be nearly real time.
Patient-services data may follow another cadence.
Putting these sources into the same technology environment does not automatically make them analytically compatible. Before an organization can reliably use advanced analytics or AI, it still needs to address questions around:
identity, definitions, lineage, quality, timing, integration, validation, and business meaning.
This is why simply purchasing another data platform does not necessarily solve the commercial analytics problem.
4. Organizational Silos May Be the Hardest Silos
It’s also important to recognize that some of the toughest barriers are not technical. Different functions often own different parts of the commercial picture:
Commercial may own brand performance.
Market Access may own payer analytics.
Patient Services may own hub performance.
Medical may manage scientific engagement data.
Finance may own forecasting assumptions.
IT or Data Engineering may manage infrastructure.
Agencies and external vendors may own important analytical processes.
Each team can be doing excellent work independently while the organization still struggles to develop a unified view of performance.
That creates a leadership problem:
Who connects the dots?
Who determines which questions should take priority?
Who defines common KPIs?
Who decides which datasets actually matter?
Who identifies conflicting assumptions?
Who challenges whether another dashboard is necessary?
Who ensures vendors aren't solving the same problem independently?
And ultimately:
Who translates the combined information into a decision for leadership?
This is where analytics needs to evolve from a reporting function into a decision-support capability.
Why “Put Everything in One Place” Is the Wrong Goal
There is an understandable desire to create a single source of truth. But in a complex biopharma environment, one physical repository is not necessarily the same thing as one trusted analytical view of the business. An organization can centralize enormous volumes of data and still struggle to answer basic questions.
For example:
Why is brand performance changing?
Is it caused by:
Diagnosis trends?
New patient starts?
Access restrictions?
Payer mix?
Specialty pharmacy fulfillment?
Patient abandonment?
HCP adoption?
Competitive activity?
Field execution?
Marketing effectiveness?
Persistence?
A combination of several factors?
The value is not in simply connecting the datasets. The value comes from knowing which data should be connected for that particular business question—and how to interpret the resulting evidence. That is a different capability.
AI Makes This Problem More Important
AI can process information at extraordinary scale. But scale does not automatically create business value. If the underlying environment contains inconsistent definitions, questionable data quality, unclear ownership, incompatible datasets, or ambiguous business objectives, AI can potentially accelerate the confusion rather than eliminate it.
That is why an organization's first AI question should not necessarily be: “Where can we deploy AI?” A better starting point is: “Which decisions are we trying to improve?”
Then work backward: Business Question → Data → Rights & Governance → Quality → Analytics → Insight → Decision → AI.
The ‘From Question to Action’ infographic below provides a more detailed view of this framework.
Where can automation, predictive analytics, or AI improve the speed, scale, or quality of that process? That sequencing changes the conversation from AI adoption to AI-enabled decision-making.
From Data-Ready to Decision-Ready
One of the most useful shifts organizations can make is to stop thinking only about whether data is “AI-ready.” The more important question may be: Is the organization decision-ready? Before scaling analytics or AI, leadership should be able to answer several basic questions:
What are our highest-priority business decisions?
Which data sources support those decisions?
Who owns each source?
Which KPIs and definitions are trusted across functions?
Which data can appropriately be linked and used?
Where are the most important data-quality gaps?
Which analytical capabilities should be internal versus external?
Which vendors are responsible for which part of the ecosystem?
Where can advanced analytics or AI materially improve a decision or workflow?
If those answers are unclear, another platform may not solve the underlying problem. It may simply add another layer to an already fragmented environment.
The Role of Commercial Analytics Leadership
This is where senior analytics leadership becomes particularly important. The role is not simply to manage dashboards or analytical models. Effective analytics leadership connects:
Commercial Strategy + Business Questions + Data + Governance + Analytics + Technology + Vendors + Executive Decisions.
For emerging and growing biopharma organizations, however, building an entire senior analytics organization early in commercialization may not always be practical. A fractional leadership model can provide an alternative. An experienced fractional analytics leader can help an organization:
Establish commercial analytics priorities
Define KPI and performance frameworks
Assess data and analytics readiness
Identify critical gaps across data, technology, governance, and vendors
Translate commercial questions into analytical requirements
Coordinate internal functions and external analytics partners
Evaluate advanced analytics and AI opportunities
Establish scalable decision-making processes
Translate complex results into executive-level recommendations
The objective is not to replace IT, Data Engineering, Privacy, Legal, or specialized analytics partners. It is to connect those capabilities to the commercial decisions the organization needs to make.
The Goal Is Not More Data. It Is Better Decisions. Biopharma companies do not necessarily need every dataset connected to every other dataset.
They need to know:
Which information matters.
Which connections create value.
Which controls are required.
Which insights can change a decision.
And increasingly: Where AI can enhance that process without adding another disconnected layer of technology. The organizations best positioned to scale AI will likely not be those with the most data or the most tools. They will be the organizations that create the clearest connection between: Business Questions → Trusted Data → Insights → Decisions → Action.
At ExecAdvisers, we help biopharma and healthcare organizations strengthen that connection through executive advisory and fractional Commercial Analytics & Insights leadership—helping leadership teams build scalable analytics capabilities and determine where advanced analytics and AI can create meaningful business value.
From fragmented data to confident decisions.
References & Regulatory Sources
U.S. Department of Health & Human Services (HHS), Office for Civil Rights — HIPAA Privacy Rule: Minimum Necessary Standard. Supports the discussion that covered entities generally must make reasonable efforts to limit PHI use, disclosure, and requests to the minimum necessary for the intended purpose, subject to exceptions. HHS Minimum Necessary Guidance
HHS — Guidance Regarding Methods for De-identification of Protected Health Information. Supports the article's discussion of de-identified patient-level data and the two HIPAA de-identification methods: Expert Determination and Safe Harbor. HHS De-identification Guidance
HHS — Business Associate Agreement requirements/model provisions. Supports the point that contractual arrangements can govern how PHI is accessed, used, disclosed, protected, and passed to subcontractors or other parties. HHS Model Business Associate Agreement
U.S. Food and Drug Administration — Electronic Systems, Electronic Records, and Electronic Signatures in Clinical Investigations: Questions and Answers. Supports the article's discussion of 21 CFR Part 11, regulated electronic records, reliability, integrity, and controls around clinical-investigation systems. The current FDA final guidance was issued in October 2024. FDA Electronic Records and Part 11 Guidance
European Commission — Principles of the GDPR. Supports the discussion of purpose limitation, data minimization, storage limitation, accuracy, security/confidentiality, and accountability, all of which can affect how biopharma organizations design data-access and integration processes involving EU personal data. European Commission — GDPR Principles
European Commission — Rules on International Data Transfers. Supports the discussion of added requirements when EU/EEA personal data is transferred to countries outside the EEA, including mechanisms such as adequacy decisions, Standard Contractual Clauses, and Binding Corporate Rules. European Commission — International Data Transfers
Washington State Attorney General — My Health My Data Act. Supports the point that privacy regulation increasingly covers consumer health information outside traditional HIPAA coverage. Washington describes the Act as protecting personal health data that falls outside HIPAA and imposing protections related to collection and sharing. Washington My Health My Data Act Information
Disclaimer: This article is intended for general informational purposes and does not constitute legal, privacy, regulatory, or compliance advice. Organizations should consult their legal, privacy, regulatory, and compliance professionals regarding specific data uses and requirements.
Comments